DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells

被引:30
作者
Iwaizumi, Moriya [1 ]
Tseng-Rogenski, Stephanie [1 ]
Carethers, John M. [1 ]
机构
[1] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA
关键词
5-FU; colorectal cancer; mismatch repair system; heteroduplex plasmid; ADJUVANT THERAPY; COLON-CARCINOMA; FLUOROURACIL; LEVAMISOLE; EFFICACY; MUTATION; 8-HYDROXYGUANINE; CHEMOTHERAPY; APOPTOSIS; EXTRACTS;
D O I
10.4161/cbt.12.8.17169
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: 5-fluorouracil (5-FU)-based chemotherapy is the standard treatment for advanced stage colorectal cancer (CRC) patients. Several groups including ours have reported that stage II-III colorectal cancer patients whose tumors retain DNA Mismatch repair (MMR) function derive a benefit from 5-FU, but patients with tumors that lost MMR function do not. Although, MMR recognition of 5-FU incorporated in DNA has been demonstrated biochemically, it has not been demonstrated within cells to execute 5-FU cytotoxicity. Aim: To establish an efficient construction model for 5-FU within DNA and demonstrate that 5-FU incorporated into DNA can trigger cellular cytotoxicity executed by the DNA MMR system. Methods: We constructed a 5FdU-containing heteroduplex plasmid (5FdU plasmid) and 5FdU-containing linear ds-DNA (5FdU linear DNA), and transfected these into MMR-proficient, hMLH1(-/-) and hMSH6(-/-) cells. We observed cell growth characteristics of both transfectants for 5-FU-induced cytotoxicity. Results: MMR-proficient cells transfected with the 5FdU plasmid but not the 5FdU linear DNA showed reduced cell proliferation by MTS and clonogenic assays, and demonstrated cell morphological change consistent with apoptosis. In MMR-deficient cells, neither the 5FdU plasmid nor 5FdU linear DNA induced cell growth or morphological changes different from controls. Conclusion: 5FdU as heteroduplex DNA in plasmid but not linear form triggered cytotoxicity in a MMR-dependent manner. Thus 5-FU incorporated into DNA, separated from its effects on RNA, can be recognized by DNA MMR to trigger cell death.
引用
收藏
页码:756 / 764
页数:9
相关论文
共 34 条
[11]   CHEMICAL CONSEQUENCES OF INCORPORATION OF 5-FLUOROURACIL INTO DNA AS STUDIED BY NMR [J].
KREMER, AB ;
MIKITA, T ;
BEARDSLEY, GP .
BIOCHEMISTRY, 1987, 26 (02) :391-397
[12]   SURGICAL ADJUVANT THERAPY OF LARGE-BOWEL CARCINOMA - AN EVALUATION OF LEVAMISOLE AND THE COMBINATION OF LEVAMISOLE AND FLUOROURACIL [J].
LAURIE, JA ;
MOERTEL, CG ;
FLEMING, TR ;
WIEAND, HS ;
LEIGH, JE ;
RUBIN, J ;
MCCORMACK, GW ;
GERSTNER, JB ;
KROOK, JE ;
MALLIARD, J ;
TWITO, DI ;
MORTON, RF ;
TSCHETTER, LK ;
BARLOW, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) :1447-1456
[13]   Measurement of DNA mismatch repair activity in live cells [J].
Lei, XF ;
Zhu, Y ;
Tomkinson, A ;
Sun, LZ .
NUCLEIC ACIDS RESEARCH, 2004, 32 (12) :e100
[14]   An Msh2 point mutation uncouples DNA mismatch repair and apoptosis [J].
Lin, DP ;
Wang, YX ;
Scherer, SJ ;
Clark, AB ;
Yang, K ;
Avdievich, E ;
Jin, B ;
Werling, U ;
Parris, T ;
Kurihara, N ;
Umar, A ;
Kucherlapati, R ;
Lipkin, M ;
Kunkel, TA ;
Edelmann, W .
CANCER RESEARCH, 2004, 64 (02) :517-522
[15]   The mismatch repair-mediated cell cycle checkpoint response to fluorodeoxyuridine [J].
Liu, Angen ;
Yoshioka, Ken-ichi ;
Salerno, Vincenzo ;
Hsieh, Peggy .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2008, 105 (01) :245-254
[16]   DNA mismatch repair-dependent response to fluoropyrimidine-generated damage [J].
Meyers, M ;
Wagner, MW ;
Mazurek, A ;
Schmutte, C ;
Fishel, R ;
Boothman, DA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (07) :5516-5526
[17]   A role for DNA mismatch repair in sensing and responding to fluoropyrimidine damage [J].
Meyers, M ;
Hwang, A ;
Wagner, MW ;
Bruening, AJ ;
Veigl, ML ;
Sedwick, WD ;
Boothman, DA .
ONCOGENE, 2003, 22 (47) :7376-7388
[18]   Mismatch repair in replication fidelity, genetic recombination, and cancer biology [J].
Modrich, P ;
Lahue, R .
ANNUAL REVIEW OF BIOCHEMISTRY, 1996, 65 :101-133
[19]   LEVAMISOLE AND FLUOROURACIL FOR ADJUVANT THERAPY OF RESECTED COLON-CARCINOMA [J].
MOERTEL, CG ;
FLEMING, TR ;
MACDONALD, JS ;
HALLER, DG ;
LAURIE, JA ;
GOODMAN, PJ ;
UNGERLEIDER, JS ;
EMERSON, WA ;
TORMEY, DC ;
GLICK, JH ;
VEEDER, MH ;
MAILLIARD, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (06) :352-358
[20]   FLUOROURACIL PLUS LEVAMISOLE AS EFFECTIVE ADJUVANT THERAPY AFTER RESECTION OF STAGE-III COLON-CARCINOMA - A FINAL REPORT [J].
MOERTEL, CG ;
FLEMING, TR ;
MACDONALD, JS ;
HALLER, DG ;
LAURIE, JA ;
TANGEN, CM ;
UNGERLEIDER, JS ;
EMERSON, WA ;
TORMEY, DC ;
GLICK, JH ;
VEEDER, MH ;
MAILLIARD, JA .
ANNALS OF INTERNAL MEDICINE, 1995, 122 (05) :321-326